Mydecine Innovations Group Inc.
MYCOF
$0.10
-$0.14-59.53%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 833.20K | 1.24M | 1.62M | 1.81M | 2.63M |
| Depreciation & Amortization | -- | -- | -- | -- | 0.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.10M | 182.50K | 1.66M | 1.86M | 5.13M |
| Operating Income | 1.10M | -182.50K | -1.66M | -1.86M | -5.13M |
| Income Before Tax | 1.64M | 125.30K | -1.82M | -2.36M | -9.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.64 | 0.13 | -1.82 | -2.36 | -9.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.64M | 125.30K | -1.82M | -2.36M | -9.15M |
| EBIT | 1.10M | -182.50K | -1.66M | -1.86M | -5.13M |
| EBITDA | 1.45M | 255.60K | -1.39M | -1.85M | -5.12M |
| EPS Basic | 1.33 | 0.10 | -1.48 | -2.01 | -8.52 |
| Normalized Basic EPS | 0.36 | -0.40 | -1.35 | -1.62 | -5.33 |
| EPS Diluted | 1.33 | 0.10 | -1.48 | -2.01 | -8.52 |
| Normalized Diluted EPS | 0.36 | -0.40 | -1.35 | -1.62 | -5.33 |
| Average Basic Shares Outstanding | 4.94M | 4.94M | 4.93M | 4.77M | 4.52M |
| Average Diluted Shares Outstanding | 4.94M | 4.94M | 4.93M | 4.77M | 4.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |